Company Overview

Repligen Corporation is a life sciences company that develops and commercializes bioprocessing technologies used in the production of biologic drugs. The company operates within the biopharmaceutical manufacturing and life sciences tools industries, supplying critical components and systems that enable the efficient, scalable, and compliant production of biologics such as monoclonal antibodies, vaccines, cell and gene therapies, and recombinant proteins. Repligen’s offerings are primarily consumable or recurring-use products, which are closely tied to customer production volumes.

The company’s core revenue drivers include downstream purification technologies, fluid management solutions, and process analytics. Repligen serves biopharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), and research institutions, with a strong emphasis on late-stage clinical and commercial-scale production. Founded in 1981, Repligen originally focused on protein-based therapeutics before transitioning in the 2010s toward a pure-play bioprocessing tools provider through divestitures and targeted acquisitions, significantly reshaping its strategic focus and growth profile.

Business Operations

Repligen organizes its business around several key operating segments that reflect stages of the bioprocessing workflow. Its primary segments include Filtration, Chromatography, Process Analytics, and Proteins, each contributing consumable products and systems used in biologic drug manufacturing. Revenue is generated largely through recurring sales of single-use consumables, resins, ligands, filters, and analytics devices, with additional contributions from capital equipment and long-term supply agreements.

Operations span both domestic and international markets, with manufacturing, R&D, and commercial activities distributed across North America, Europe, and Asia. Repligen controls proprietary technologies such as affinity ligands, hollow fiber filtration systems, and in-line process monitoring tools. The company operates through multiple subsidiaries integrated into its platform and maintains commercial relationships with major biopharmaceutical companies and CDMOs, embedding its products deeply into customer manufacturing processes.

Strategic Position & Investments

Repligen’s strategic direction emphasizes organic growth supplemented by selective acquisitions that expand its technology portfolio and increase exposure to high-growth biologics modalities. The company focuses on technologies that improve yield, reduce cost, and enable single-use and continuous manufacturing, positioning itself as a critical supplier across the downstream bioprocessing workflow. Growth initiatives prioritize expanding consumables penetration in commercial-scale biologics manufacturing and increasing content per customer process.

Historically, Repligen has completed several acquisitions to enhance its capabilities, including Spectrum Laboratories, C Technologies, and Ravenscroft Development, which strengthened its filtration, process analytics, and ligand development offerings. The company continues to invest in emerging areas such as cell and gene therapy manufacturing, advanced process analytics, and intensified downstream processing, while maintaining a disciplined approach to capital allocation.

Geographic Footprint

Repligen is headquartered in Waltham, Massachusetts, and maintains a significant operational presence across North America, Europe, and Asia-Pacific. The company operates manufacturing and development facilities in the United States, Ireland, Sweden, Germany, and the United Kingdom, supporting global supply to biopharmaceutical customers.

International markets represent a substantial portion of revenue, with growing exposure to biologics manufacturing expansion in Europe and Asia, including China, Japan, and South Korea. Repligen’s global footprint enables close collaboration with multinational biopharmaceutical companies and regional CDMOs, reinforcing its role as a critical supplier in regulated manufacturing environments worldwide.

Leadership & Governance

Repligen is led by an executive team with extensive experience in bioprocessing, life sciences tools, and industrial operations. The leadership emphasizes a strategy centered on high-margin consumables, customer-centric innovation, and disciplined execution, with a focus on long-term value creation through technology leadership and operational excellence.

Key executives include:

• Anthony J. Hunt – President and Chief Executive Officer
• Jason Garland – Chief Financial Officer
• Andrew Baldwin – Executive Vice President, Global Operations
• Craig Markham – Senior Vice President, Corporate Strategy and Business Development
• Nicole Boucher – Senior Vice President, Human Resources

The company operates under a governance framework aligned with U.S. public company standards, with oversight by an independent board of directors and a focus on regulatory compliance, risk management, and shareholder interests.